

| West Yorkshire Integrated Care Board (WY ICB) | | | | | | |
|---|--|------------------|---|-------------------|-----------------|--|
| Policy | Laser treatments not covered elsewhere | | | ICB Ref | Planned care | |
| First Issue Date | To be confirmed | Current version: | 1 | Last reviewed: | May 2022 | |
| Review date | To be confirmed | Contact | West Yorkshire Health and Care Partnership (WY HCP) wyhcp.plannedcare@nhs.net | | | |
| Clinical Reviewer | WY HCP | Approved by | WY ICB | | | |
| Policy exclusions | | | | | | |

This policy relates to those circumstances where laser treatments may be required, but that are not covered in other policies.

Laser treatments for certain conditions are routinely commissioned. Laser treatments other than outlined within this policy or other WY ICB policies are considered cosmetic and will not be funded.

An enhancement for people living in Bradford District and Craven, and Calderdale, Kirklees and Wakefield as this policy only existed in the Leeds area even though there may have been a service provision for these specified laser treatments in the other places in West Yorkshire mentioned above.

Policy inclusion criteria

Some conditions requiring treatment with medical laser are routinely commissioned. Any requests that are not medically necessary are considered cosmetic and will not be funded. Medical laser treatment may be offered to patients in the following circumstances;

Inflammatory or infiltrated dermatoses unresponsive to alternative therapy to include:

- Extensive xanthomata
- Amyloidosis

Symptomatic viral warts ONLY associated with immunodeficiency states including organ transplant patients with severe symptomatic viral warts should be referred to a Dermatologist in secondary care for assessment, although any recommended treatment may be provided in the community. Exludes Asymptomatic viral warts or viral warts in the absence of an immunodeficiency state.

NB Laser treatment is considered cosmetic and/ or experimental in the following indications and will not be routinely funded except following exceptionality approval, where the condition is severe and debilitating, and where standard treatments are considered ineffective or contraindicated. This would be after assessment from at the advice of a specialist Laser Dermatology Consultant and would only be considered in patients with DLQI

>10 where it is felt any potential risks from the treatment would outweigh the benefits

- Atopic dermatitis
- Lichen sclerosus
- Morphea (scleroderma of the skin)
- Mycosis fungoides
- Onychomycosis
- Prurigo nodularis
- Vulval intraepithelial neoplasia
- Localised severe psoriasis or eczema